Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:PDDPF) announced Monday that its joint-disease drug Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been added to the public drug plan in Quebec.
The Toronto-based specialty pharmaceutical company said the drug has been approved for inclusion on the List of Medications-Basic Plan and the List of Medications-Institutions administered by the Régie de l’assurance maladie du Québec (RAMQ) from August 19.
According to the company, Quebec’s health technology assessment agency, or the Institut national d'excellence en santé et en services sociaux (INESSS) recommended that TH be included on the List of Medications covered by the basic prescription drug insurance plan, and the List of Medications – Institutions which includes hospitals with no restrictions on reimbursement.
In a statement, Medexus CEO Ken d’Entremont said: “We are pleased about the addition of TH to the public drug plan formularies in Quebec and look forward to advancing the commercial rollout of TH in additional provinces across Canada over the coming months.”
He added: “With the inclusion of our TH on RAMQ’s List of Medications, we are able to access a large group of children and adult patients suffering from debilitating forms of joint disease, who previously could not get the product due to a long-standing shortage of TH in Canada.”
TH is the longest acting corticosteroid injection used to treat many different types of inflammatory conditions, often lasting twice as long as comparator products, the company said.
“We believe TH will transform the treatment of many subacute and chronic inflammatory joint diseases as it provides a longer duration of action, with fewer injections, compared to other corticosteroid injections and intra-articular steroids,” added d’Entremont.
“By reducing the number of injections, TH offers a safer and more cost-effective solution, thereby reducing the number of hospital visits, which is particularly important in the current coronavirus (COVID-19) environment.”
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive